- Conditions
- Breast Cancer
- Interventions
- Bevacizumab, Abraxane
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 691
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- YM155, Docetaxel
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Pleasant Hill, California • Lakeland, Florida + 4 more
- Conditions
- Breast Cancer Metastatic
- Interventions
- Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more
- Conditions
- PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
- Interventions
- Leflunomide
- Drug
- Lead sponsor
- Deborah Doroshow
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
- Interventions
- BG-68501, Fulvestrant, BGB-43395
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
- Conditions
- Breast Cancer
- Interventions
- PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,037 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more
- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Ribociclib, Fulvestrant, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 11
- States / cities
- Anaheim, California • Palo Alto, California • Jacksonville, Florida + 8 more
- Conditions
- Breast Cancer
- Interventions
- Everolimus, Exemestane, Tamoxifen, Fulvestrant, Anastrozole, Letrozole, Toremifine
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more
- Conditions
- Metastatic Breast Cancer, Breast Neoplasms
- Interventions
- Talazoparib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Neoplasms
- Interventions
- Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 46
- States / cities
- Hot Springs, Arkansas • Cerritos, California • Long Beach, California + 35 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ATX-898, ATX-898, fulvestrant, ribociclib
- Drug
- Lead sponsor
- Antares Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Fort Worth, Texas • Houston, Texas • San Antonio, Texas + 2 more
- Conditions
- Breast Cancer
- Interventions
- Dovitinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis, Run-in (short pre-surgery course) of endocrine-targeted therapy
- Drug · Procedure · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Biomarker Analysis, Enzalutamide, Pharmacological Study, Taselisib
- Other · Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 9 more
- Conditions
- HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer, Stage IV Inflammatory Breast Carcinoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets, Exemestane Tablets
- Drug
- Lead sponsor
- Tolmar Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 17
- States / cities
- Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more
- Conditions
- Breast Cancer
- Interventions
- Elacestrant, Onapristone
- Drug
- Lead sponsor
- Context Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Cancer, Metastatic HER2-negative Breast
- Interventions
- Cyclophosphamide, Mesothelin-targeted T cells, AP1903
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Cancer
- Interventions
- Gedatolisib, Palbociclib, Letrozole, Fulvestrant
- Drug
- Lead sponsor
- Celcuity Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more
- Conditions
- HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- Romidepsin, Abraxane
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- Sedona, Arizona • Long Beach, California • Charlotte, North Carolina + 3 more
- Conditions
- Breast Cancer
- Interventions
- Erlotinib with neoadjuvant chemotherapy
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Everolimus, TRC105
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Breast Cancer
- Interventions
- A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California